UPDATE 1-U.S. FDA approves Alkermes' schizophrenia drug Aristada

Oct 5 (Reuters) - Alkermes PLC said on Monday the U.S. Food and Drug Administration approved its extended-release injectable version of schizophrenia treatment Abilify.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.